Company Interview / The Aussie small cap hitting the right nerve in key US market

Key Points:

Nerve Aligned Nerve Cuff approved for use in extensive US military and veteran hospitalsFive product lines on the market with a sixth pending, including deep dermal and amniotic tissue devicesReNerve positioned alongside PolyNovo (ASX:PNV) and Aroa Biosurgery (ASX:ARX) in tissue-based device spaceInternational expansion underway with approvals in Asia and the Middle East

Dr Julian Chick of ReNerve (ASX; RNV) highlights the recent approval of the Nerve Aligned Nerve Cuff for use across US Department of Defense and Veterans Affairs healthcare systems. Chick states this milestone enables ReNerve to access a significant market of hospitals and patients, giving broad exposure and accelerating adoption of their flagship product. The device reportedly reduces postoperative pain and offers what Chick describes as best-in-class performance for peripheral nerve repair. The approval helps position ReNerve’s expanding product suite for inclusion in US military and trauma centres, broadening its reach and potential sales in the largest addressable market.

Chick outlines that ReNerve now markets five product ranges, with a sixth to launch soon. The company’s offerings extend beyond the nerve cuff to include deep dermal and amniotic tissue products, as well as an upcoming conduit device. Chick draws parallels to companies like PolyNovo (ASX:PNV) and Aroa Biosurgery (ASX:ARX), referencing ReNerve’s focus on purpose-designed, tissue-based devices. A partnership with Berkley Biologics has brought a complementary employee range to market, marking the firm’s transition from R&D to commercialisation.

International strategy is also at the forefront, with regulatory approvals secured in Hong Kong, New Zealand, and the Middle East, and anticipated in India. Chick points to robust funding and expects meaningful revenue growth as the company targets profitability by 2025-2026.